A 52-year-old man with metastatic pancreatic cancer develops acute DIC with skin necrosis, acute kidney injury, and bleeding. Which of the following mechanisms is NOT involved in the pathogenesis of DIC?

Explanation

## Pathogenic Mechanisms of DIC **Key Point:** DIC is initiated by extrinsic (tissue factor) and intrinsic (contact activation) pathways, leading to uncontrolled thrombin generation and consumption coagulopathy. Antithrombin III is not produced in response to DIC—it is consumed. ## Initiation Pathways in DIC ```mermaid flowchart TD A[Trigger: Malignancy, Sepsis, Trauma]:::outcome --> B{Pathway Activation}:::decision B -->|Extrinsic| C[Tissue Factor Release]:::action B -->|Intrinsic| D[Factor XII Activation]:::action C --> E[Factor VII Activation]:::action D --> F[Factor XI, IX Activation]:::action E --> G[Common Pathway]:::action F --> G G --> H[Thrombin Generation]:::action H --> I[Fibrin Deposition + Platelet Consumption]:::urgent I --> J[Microthrombi Formation]:::urgent J --> K[Organ Damage + Secondary Fibrinolysis]:::urgent ``` ## Key Mechanisms in DIC Pathogenesis | Mechanism | Role in DIC | Status in DIC | |-----------|------------|---------------| | Tissue Factor (TF) release | Initiates extrinsic pathway | **Increased** | | Factor XII activation | Initiates intrinsic pathway via contact | **Increased** | | Thrombin generation | Converts fibrinogen to fibrin | **Excessive** | | Antithrombin III | Natural anticoagulant, inhibits thrombin | **Decreased (consumed)** | | Protein C / Protein S | Natural anticoagulants | **Decreased (consumed)** | | Fibrinolysis | Breaks down fibrin clots | **Secondary activation** | **High-Yield:** Antithrombin III is **not produced** in response to DIC. Instead, it is progressively consumed as it binds to and neutralizes activated clotting factors. Low antithrombin III levels indicate severe DIC and poor prognosis. Hepatic synthesis of antithrombin III is normal or even increased, but the rate of consumption far exceeds production. **Clinical Pearl:** The paradox of DIC is that despite massive thrombin generation and fibrin deposition (causing thrombosis and organ damage), patients bleed because clotting factors and platelets are consumed faster than they can be replaced. This is why DIC management requires both anticoagulation (to stop thrombin generation) and replacement therapy (FFP, cryoprecipitate, platelets). ## Why Antithrombin III Is Consumed, Not Produced 1. **Antithrombin III is a serine protease inhibitor (serpin)** that irreversibly binds to thrombin and other activated factors 2. **In DIC, thrombin is generated excessively**, consuming all available antithrombin III 3. **Hepatic synthesis cannot keep pace** with consumption, resulting in net depletion 4. **Low antithrombin III is a marker of severity** and indicates the coagulation cascade is overwhelming the natural anticoagulant system **Mnemonic:** **TISSUE FACTOR RULES DIC** = **T**issue Factor release (extrinsic), **I**ntrinsic pathway (Factor XII), **S**erine proteases activated, **S**econdary fibrinolysis, **U**ncontrolled thrombin, **E**ndothelial damage, **F**ibrin deposition, **A**ntithrombin consumed, **C**ontact activation, **T**hrombosis + bleeding, **O**rgan failure, **R**eleased phospholipids, **U**niversal pathway activation, **L**ow platelets, **E**levated D-dimer, **S**evere coagulopathy.